QBPC PI CME Performance Dashboards Reference Guide
|
|
- Darcy Warner
- 5 years ago
- Views:
Transcription
1 QBPC PI CME Performance Dashboards Reference Guide QBPC PI-CME has been designed to enhance knowledge, competency and performance in the management of patients with cardiovascular (CV) metabolic risk factors. The QBPC PI-CME program provides ongoing attributed patient data analysis and tailored CME opportunities to participating physicians to address gaps in care and ensure patients are treated according to national guidelines. Practices are benchmarked against QBPC clinical measure target goals, QBPC peer practices, Southeastern regional practices and nationally with other Symphony Performance Health, Inc. (formerly MDdatacor) enrolled practices. The QBPC PI-CME Performance Dashboards are generated by The Consortium for Southeastern Hypertension Control (COSEHC). Please refer to the sample report found on pages 6 and 7 of this guide. 1. When viewing your report, you will note the Quality Blue Primary Care (QBPC) logo and the Integrated Medical Processes, LLC (IMP) logo in the upper top corners. IMP is a physicianled, clinical integration consultancy focused on population management and value-based care models and IMP s IMPACT program serves as the foundation for QBPC, providing the framework and implementation strategy to enable care transformation. 2. Looking at the middle top heading, you will find the title of the report: QBPC PI-CME Performance. 3. The second line in the middle heading denotes that this is a Baseline Report. Once you have received your baseline report, additional reports will be denoted here as Follow-up Reports. 4. The third line in the middle heading gives the Practice site location. The rationale for using the practice site location is because from a performance improvement viewpoint, different sites may operate differently in terms of the staff and their processes. Please note that within MDinsight you can drill down to each individual physician, but from the performance improvement perspective, process changes happen at the location level. 5. The Report Period is noted just below the IMP logo. This is the date range which the data was retrieved for the reporting period, meaning relevant biometric measures are analyzed for eligible patients only if they occurred within the prior 12 months of the reporting period listed on the report. Before dissecting the sections of the performance dashboards, please note that only eligible patients are counted in the report. An eligible patient is defined as a BCBSLA member patient who has had a clinic visit within the 24 months prior to the end of the reporting period. Again, relevant biometric measures are analyzed for eligible patients only if they occurred within the 12 months of the reporting period listed on your report. Eligible patients without a relevant biometric measure within the 12 months prior to the end of the reporting period are considered out of control and are recorded as zero in calculating the percent of a measure s attainment. Page 1
2 The performance dashboard reports are formatted into sections according to the clinical suites assigned by MDinsight: 6. The top section reflects the percent of eligible patients in a practice attaining the defined biometric measures. NOTE: The emphasis of this section is that this is all BCBSLA patients including patients that do not have a chronic disease diagnosis. This gives a higher level population view for all BCBSLA patients. The first column, Metric, lists three measures, Blood Pressure, LDL Cholesterol and Non-HDL Cholesterol. The second column, ALL BCBSLA PATIENTS, is divided into two sections. The section titled Your Practice refers to your practice site location and includes data for all physicians at that specific site. This is their performance level. The section titled All of QBPC refers to all BCBSLA patients. When looking at the Blood Pressure measure in the example above, the percentage of eligible patients in your practice that attained a blood pressure reading <140/90 is 71% compared to 57% for all of QBPC. The third column, BENCHMARKS, is divided into two sections, Southeastern and National. The Southeastern benchmark is provided by COSEHC and will benchmark QBPC against COSEHC locations from the southeast region. The National benchmark, which is highlighted in gray, will be provided by Symphony Performance Health, Inc. (formerly MDdatacor) and will benchmark QBPC practices against other Symphony Performance Health, Inc. enrolled practices across the nation. When looking at the Blood Pressure measure in the example above, your practice had 71% and all of QBPC had 57%. Your practice at 71% compared to the benchmark for all of QBPC is more than 5 percentage points above all of QBPC at 57%. Since it is greater than 5 percentage points in absolute terms, then you receive a GREEN dot in the comparison column vs. ALL OF QBPC which denotes that your practice is Above Average by greater than 5%. When compared to the Southeastern Benchmark, your practice at 71% is > 5 percentage points below the Southeastern benchmark at 80%. Since your practice is below by greater than 5 percentage points of the benchmark (Average), you will receive a RED dot in the comparison Page 2
3 column vs. SOUTHEAST. If your practice is within + or - 5 percentage points of the benchmark you will receive a YELLOW dot in the comparison column. 7. The bottom sections under QBPC Clinical Quality Measures, contains the six suites that are in MDinsight: Optimal Diabetes Care, Optimal Vascular Care, Optimal CKD Care, Hypertension Control, Vascular Pharmacy Measure and CKD Pharmacy Measure. These suites are not inclusive of all BCBSLA patients and only include the members in the reporting time period with the specific disease diagnosis. Each measure in the respective suite reflects the percentage of eligible patients attaining the target goal. Page 3
4 The Optimal Composite reflects the percentage of patients that have met all listed measures in the suite. You will note that the Optimal Diabetes Care suite has four target measures: HbA1c (<8.0%), Blood Pressure (<140/90mm Hg), LDL Cholesterol (<100mg/dl) and Non-smoker. When looking at the Optimal Composite for Diabetes Care above, your practice is at 25% and all of QBPC is at 13%. Compared to the ALL OF QBPC benchmark, your practice is greater than 5 percentage points above and you receive a GREEN dot in the comparison column vs. ALL OF QBPC. NOTE: The Optimal Composite is only compared to ALL of QBPC because we have no great benchmarks to compare this against. In the Optimal CKD Care suite, the Optimal Composite reflects the percent attainment* of measures in the suite of eligible patients (patients with diagnosis of Chronic Kidney Disease, a Diagnosis code for proteinuria or readings of lab/other test values outlined in the Policy and Procedure Manual for this measure). *Only attainment of the blood pressure measure is required if the patient is without proteinuria; if proteinuria is present, both the blood pressure measure and the ACE/ARB Rx measure must be met. When looking at the Optimal CKD Care suite example above, your practice has 90% of patients with proteinuria on ACE/ARB Rx compared to the benchmark for all of QBPC of 18%. Compared to the ALL OF QBPC benchmark, your practice is greater than 5 percentage points above and you receive a GREEN dot in the comparison column vs. ALL OF QBPC. Page 4
5 The Vascular Pharmacy Measure is designed to reflect compliance to statin class of medications used to treat hyperlipidemia. The On Statin measure reflects the percentage of patients with vascular disease on a statin medication. The Proportion of Days Covered measure estimates the percentage of patients that have medications available to consume for 80% of the days remaining in the year from the first dispensed date through the end of the year. The CKD Pharmacy Measure is similar to the Vascular Pharmacy Measure and is designed to reflect compliance with and essential medication for the medical condition; which in this case is Chronic Kidney Disease WITH Proteinuria. The ACE/ARB Rx reflects only those with significant proteinuria (i.e. 300mg/g using a spot Cr/Albumin test) who are on an ACE/ARB. The Proportion of Days Covered measure also estimates the patients who fill their medication so that they have medications available to consume 80% or more days of the year. Page 5
6 Page 6
7 7 Page 7
Practical and Detail Oriented Quality Improvement Intervention Model for Cardiovascular Disease
Practical and Detail Oriented Quality Improvement Intervention Model for Cardiovascular Disease Brian Forrest, MD ABFM Specialist In Clinical Hypertension (ASH) Founder- Access Hypertension and Cardiovascular
More informationQBPC Claims Based Provider Quick Reference Guide
QBPC Claims Based Provider Quick Reference Guide Category: Diabetes Chronic Suite ICD-10-CM diagnosis HbA1c Test Codes LOINC Evidence of Treatment for Nephropathy Codes E10; E11; E13 83036-37 17856-6,
More informationCommercial Business Medical Cost Target
Commercial Business Medical Cost Target Measurement Period Handbook For Enhanced Personal Health Care Measurement Period beginning: April 1, 2018 CBMCT 040118 V3 Introduction Welcome to your Commercial
More informationUnderstanding new international guidelines to tackle CV Risk: A practical model John Deanfield, MD UCL, London United Kingdom s
Understanding new international guidelines to tackle CV Risk: A practical model John Deanfield, MD UCL, London United Kingdom s Ho Chi Minh City, Vietnam August 7, 2014 JBS 2 Risk Guidelines (2005) Based
More informationJoint Labor-Management Benefits Committee (JLMBC) COMMITTEE REPORT JLMBC MEMBERS Employee Organizations David Sanders, Chairperson
Joint Labor-Management Benefits Committee (JLMBC) COMMITTEE REPORT 19-15 JLMBC MEMBERS Employee Organizations David Sanders, Chairperson Date: April 4, 2019 To: From: Subject: JLMBC Staff LAwell Program
More informationPatient is healthy with no chronic disease or significant risk factors [16%].
AAFP Risk Level 1 Patient is healthy with no chronic disease or significant risk factors [16%]. Exclude the following chronic problems from active patient list o Depression o Diabetes Type I or Type II
More informationSTARS SYSTEM 5 CATEGORIES
TMG STARS 2018 1 2 STARS Program Implemented in 2008 by CMS. Tool to inform beneficiaries of quality of various health plans 5-star rating system Used to adjust payments to health plans (bonus to plans
More informationPresentation title. Better Health Care For Greater Cleveland Learning Collaborative March 5, Ron Adams, MD Regional Chief Internal Medicine
Better Health Care For Greater Cleveland Learning Collaborative March 5, 2010 Presentation title Ron Adams, MD Regional Chief Internal Medicine SUB TITLE HERE Prevent Heart Attacks and Strokes Every Day
More informationManaging Chronic Kidney Disease: Reducing Risk for CKD Progression
Managing Chronic Kidney Disease: Reducing Risk for CKD Progression Arasu Gopinath, MD Clinical Nephrologist, Medical Director, Jordan Landing Dialysis Center Objectives: Identify the most important risks
More informationAggregate Report Instructions
Version 2018_v4 Workplace Health Solutions Center for Workplace Health Research & Evaluation Version 2018_v4 Table of Contents Purpose.....3 Data Privacy....3 About Life's Simple 7....4 Table 1. Life's
More informationMedicare Star Ratings and the Shift to Quality- Based Payment Models. David Nau, RPh, PhD, FAPhA PQS President
Medicare Star Ratings and the Shift to Quality- Based Payment Models David Nau, RPh, PhD, FAPhA PQS President The shift to Value-Driven Healthcare The U.S. health care system is rapidly moving to value-based
More informationCommercial Business Medical Cost Target
Commercial Business Medical Cost Target Measurement Period Handbook For Enhanced Personal Health Care Measurement Period beginning: April 1, 2018 CBMCT 040118 V1 Introduction Welcome to your Commercial
More informationA: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups
A: Epidemiology update Evidence that LDL-C and CRP identify different high-risk groups Women (n = 27,939; mean age 54.7 years) who were free of symptomatic cardiovascular (CV) disease at baseline were
More informationMedicare STRIDE SM Physician Quality Program 2019 Program Overview
Medicare STRIDE SM Quality Program 2019 Program Overview Health Services- Managed by Network Medical Management 2019 Program 1 Medicare Advantage Quality Program Program Overview The Plan will support
More informationMedicare Advantage Measurement Period Handbook for Enhanced Personal Health Care Measurement Period beginning January 1, 2015
Medicare Advantage Measurement Period Handbook for Enhanced Personal Health Care Measurement Period beginning January 1, 2015 Amerivantage is an HMO plan with a contract with the New Mexico Medicare program.
More informationACC/AHA Guidelines Bulls-eyes and Misses
ACC/AHA Guidelines Bulls-eyes and Misses James Trippi, MD, FACC Diplomate American Board of Clinical Lipidology Complex Cholesterol Center of St. Vincent Health Indianapolis, IN October 18, 2014 Level
More information2012 Diabetes. Program Evaluation. Our mission is to improve the health and quality of life of our members
2012 Diabetes Program Evaluation Our mission is to improve the health and quality of life of our members Diabetes Program Evaluation Program Title: Diabetes Program Evaluation Period: January 1, 2012 December
More informationUnderstanding Your Patient Care Opportunity Report (PCOR)
Understanding Your Patient Care Opportunity Report (PCOR) Use your January/February 208 PCOR to help improve performance on Medicare Part D Clinical Star Ratings measures. Your January/February 208 Patient
More informationHUDSON HEADWATERS HEALTH NETWORK THE ROAD TO DIABETES RECOGNITION
HUDSON HEADWATERS HEALTH NETWORK THE ROAD TO DIABETES RECOGNITION Cyndi Nassivera-Cordes, RN, CRM October 4, 2010 WE DO ALL THAT Already involved with Diabetes Collaborative Adopted Evidence-Based Clinical
More informationPut your Heart before your Head
Put your Heart before your Head Alok K Gupta, MD, FAAFP, FASH Associate Professor, Outpatient Clinic since 1963, the US Congress has required the President to proclaim February "American Heart Month."
More informationReview of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More informationCare Facilitation Quality Improvement Report
Disease Management Program Clinical Outcomes for Reporting Period: 2006 Diabetes 100.0% 90.0% % of participants with diabetes 80.0% 70.0% 60.0% 50.0% 40.0% 30.0% 20.0% 10.0% 0.0% % participants with at
More informationOutline. Outline 10/14/2014 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationKey Quality of Care Measures. Blue Cross Blue Shield of Michigan Traditional, PPO and POS Members. Fourth Quarter 2003
Key Quality of Care Measures Blue Cross Blue Shield of Michigan Traditional, PPO and POS Members Fourth Quarter 2003 Blue Cross Blue Shield of Michigan is a nonprofit corporation and independent licensee
More informationNorthwestern University Feinberg School of Medicine Calculating the CVD Risk Score: Which Tool for Which Patient?
Northwestern University Feinberg School of Medicine Calculating the CVD Risk Score: Which Tool for Which Patient? Donald M. Lloyd-Jones, MD, ScM, FACC, FAHA Senior Associate Dean Chair, Department of Preventive
More informationThe Latest Generation of Clinical
The Latest Generation of Clinical Guidelines: HTN and HLD Dave Brackett Clinical Guideline Purpose Uniform approach Awareness of key details Diagnosis Treatment Monitoring Evidence based approach Inform
More informationSCIENTIFIC STUDY REPORT
PAGE 1 18-NOV-2016 SCIENTIFIC STUDY REPORT Study Title: Real-Life Effectiveness and Care Patterns of Diabetes Management The RECAP-DM Study 1 EXECUTIVE SUMMARY Introduction: Despite the well-established
More informationYour Partnership in Health Report: Chronic Conditions ABC Company and Kaiser Permanente
Your Partnership in Health Report: s ABC Company and Kaiser Permanente Measurement Period: JUL-01-2012 through JUN-30-2013 Report Date: DEC-31-2013 Commercial All Members Partnership in Health (PIH) reports:
More informationOutline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 7/23/2013. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationHYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016
HYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016 NOTHING TO DISCLOSE I, Nicole Slater, have no actual or potential conflict
More informationTime Series Analysis for selected clinical indicators from the Quality and Outcomes Framework
Time Series Analysis for selected clinical indicators from the Quality and Outcomes Framework 21-26 Title Document Type Time Series Analysis for selected clinical indicators from the Quality and Outcomes
More informationAmerican Diabetes Association 2018 Guidelines Important Notable Points
American Diabetes Association 2018 Guidelines Important Notable Points The Standards of Medical Care in Diabetes-2018 by ADA include the most current evidencebased recommendations for diagnosing and treating
More informationPharmacy Coverage Guidelines are subject to change as new information becomes available.
Ezetimibe-simvastatin 10-80 mg oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationCommercial Business Measurement Period Handbook-Medical Cost Target Model For Enhanced Personal Health Care Measurement Period beginning: 01/1/17
Commercial Business Measurement Period Handbook-Medical Cost Target Model For Enhanced Personal Health Care Measurement Period beginning: 01/1/17 CBMCT Version 010117 V3 Introduction: Welcome to your Commercial
More informationDiagnosis and Management of Type 2 Diabetes Mellitus in Adults
Quality Improvement Support: Diagnosis and Management of Type 2 Diabetes Mellitus in Adults The Aims and Measures section is intended to provide guideline users with a menu of measures for multiple purposes,
More informationProtecting the heart and kidney: implications from the SHARP trial
Cardiology Update, Davos, 2013: Satellite Symposium Protecting the heart and kidney: implications from the SHARP trial Colin Baigent Professor of Epidemiology CTSU, University of Oxford S1 First CTT cycle:
More informationImproving Quality in Type 2 Diabetes:
Improving Quality in Type 2 Diabetes: Reengineering Practices From the Inside The Endocrine Society / The Hormone Foundation American Pharmacists Association Opus Science, LLC Presenters / Disclosures
More informationArkansas Blue Cross and Blue Shield (ABCBS) Patient Centered Medical Home (PCMH) Specifications Manual
Arkansas Blue Cross and Blue Shield (ABCBS) Patient Centered Medical Home (PCMH) Specifications Manual 2017 This document is a guide to the 2017 Arkansas Blue Cross and Blue Shield Patient-Centered Medical
More informationSTRIDE SM Quality Program 2017 Program Overview
STRIDE SM Quality Program 2017 Program Overview Health Services 2017 Program 1 Quality Program Program Overview The Plan will support the efforts of the LCU and LCU Participating Providers in managing
More informationOutline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationThe Art of Cardiovascular Risk Assessment
The Art of Cardiovascular Risk Assessment Laurence S. Sperling, M.D., FACC, FACP,FAHA, FASPC Professor of Medicine (Cardiology) Professor of Global Health Director- Center for Heart Disease Prevention
More informationUpdate on Lipid Management in Cardiovascular Disease: How to Understand and Implement the New ACC/AHA Guidelines
Update on Lipid Management in Cardiovascular Disease: How to Understand and Implement the New ACC/AHA Guidelines Paul Mahoney, MD Sentara Cardiology Specialists Lipid Management in Cardiovascular Disease
More informationIs Knowing Half the Battle? Behavioral Responses to Risk Information from the National Health Screening Program in Korea
Is Knowing Half the Battle? Behavioral Responses to Risk Information from the National Health Screening Program in Korea Hyuncheol Bryant Kim 1, Suejin A. Lee 1, and Wilfredo Lim 2 1 Cornell University
More informationHealth Care Systems Research Network (HCSRN) Conference April 12, 2018 Minneapolis, MN
Health Care Systems Research Network (HCSRN) Conference April 12, 2018 Minneapolis, MN Impact of the Latest USPSTF Recommendations for Statin Use for Primary Cardiovascular Prevention on Payers and Care
More informationQUALITY IMPROVEMENT Section 9
Quality Improvement Program The Plan s Quality Improvement Program serves to improve the health of its members through emphasis on health maintenance, education, diagnostic testing and treatment. The Quality
More informationConflict of Interest Disclosure. Learning Objectives. Learning Objectives. Guidelines. Update on Lifestyle Guidelines
Conflict of Interest Disclosure Updates for the Ambulatory Care Pharmacist: Dyslipidemia and CV Risk Assessment No conflicts of interest to disclose 2014 Updates to the Updates in Ambulatory Care Pharmacy
More informationBatch Upload Instructions
Last Updated: Jan 2017 Workplace Health Solutions Center for Workplace Health Research & Evaluation Workplace Health Achievement Index 1 P A G E Last Updated: Jan 2017 Table of Contents Purpose.....Err
More informationEyes on Korean Data: Lipid Management in Korean DM Patients
Eyes on Korean Data: Lipid Management in Korean DM Patients ICDM Luncheon Symposium Sung Rae Kim MD PhD Division of Endocrinology and Metabolism The Catholic University of Korea Causes of Death in People
More information2013, American Heart Association
2013, American Heart Association Mission: Lifeline - Data, Reports and ACTION Registry - GWTG THE MISSION: BETTER HEART ATTACK CARE FOR YOUR COMMUNITY THE LIFELINE: THE AMERICAN HEART ASSOCIATION AND YOU
More informationPATIENT-IMPACT SCORECARD
UNDERSTANDING THE GSC PATIENT-IMPACT SCORECARD What is the GSC Patient-Impact Scorecard? The GSC Patient-Impact Scorecard shows pharmacy performance scores for GSC patients during the period indicated.
More informationESC/EAS Guidelines for the Management of Dyslipidaemias
ESC/EAS Guidelines for the Management of Dyslipidaemias Professor Željko Reiner, MD, PhD, FRCP(Lond), FESC, FACC University Hospital Center Zagreb School of Medicine, University of Zagreb, Croatia Declaration
More informationUpdate on New RCHC Relevant and BridgeIT Reports. Redwood Community Health Coalition Data Group Webinar November 13, 2018 By Ben Fouts, Data Analyst
Update on New RCHC Relevant and BridgeIT Reports Redwood Community Health Coalition Data Group Webinar November 13, 2018 By Ben Fouts, Data Analyst Agenda New Measures (2019) UDS: CAD QIP: Asthma Medication
More informationClinical Practice Guideline Key Points
Clinical Practice Guideline Key Points Clinical Practice Guideline 2008 Key Points Diabetes Mellitus Provided by: Highmark Endocrinology Clinical Quality Improvement Committee In accordance with Highmark
More informationThe future is here. It s just not widely distributed yet. William Gibson
The future is here. It s just not widely distributed yet. William Gibson CHRONIC KIDNEY DISEASE MANAGEMENT A NEW PARADIGM Aaron Cass, MD, FRCPC Nephrologist, Fraser Health January 22, 2014 Where Are We
More informationSection 1: 1: Trends. Section 2: 2: Comparisons to to Overall Portland Area Area Results for for
Section 1: 1: Trends 1 Patients in the Diabetes Register 2 Gender of Patients with Diabetes 2 Age of Patients with Diabetes 3 Diabetes Type 3 Duration of Diabetes 4 Weight Control 5 Hemoglobin A1c 6 Blood
More informationComposite Performance Report
Composite Performance Report 10 9 91% 8 7 65% 68% 65% 6 56% 5 4 3 2 44% 37% 48% 31% 19% 29% 1 6% Key: Report Measure Name Cohort Target Cohort Definition Formula 1 Control Blood Pressure All patients who
More informationHIGH BURDEN OF METABOLIC COMORBIDITIES IN A CITYWIDE COHORT OF HIV OUTPATIENTS
HIGH BURDEN OF METABOLIC COMORBIDITIES IN A CITYWIDE COHORT OF HIV OUTPATIENTS Evolving Health Care Needs of People Aging with HIV in Washington, DC Matthew E. Levy 1, Alan E. Greenberg 1, Rachel Hart
More informationDiabetes: Use of Adjunctive Therapy ACEs, ARBs, ASA & STATINs --Oh My! Veronica J. Brady, PhD, FNP-BC, BC-ADM, CDE Project ECHO April 19, 2018
Diabetes: Use of Adjunctive Therapy ACEs, ARBs, ASA & STATINs --Oh My! Veronica J. Brady, PhD, FNP-BC, BC-ADM, CDE Project ECHO April 19, 2018 Points to Ponder ASCVD is the leading cause of morbidity
More informationCHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH SCIENTIFIC DIRECTOR KIDNEY HEALTH RESEARCH COLLABORATIVE - UCSF CHIEF - GENERAL INTERNAL MEDICINE, SAN FRANCISCO
More informationCHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationPOTENTIAL LINKAGES BETWEEN THE QUALITY AND OUTCOMES FRAMEWORK (QOF) AND THE NHS HEALTH CHECK
POTENTIAL LINKAGES BETWEEN THE QUALITY AND OUTCOMES FRAMEWORK (QOF) AND THE NHS HEALTH CHECK Author: CHARLOTTE SIMPSON, SPECIALTY REGISTAR PUBLIC HEALTH (ST3), CHESHIRE EAST COUNCIL/MERSEY DEANERY SUMMARY
More informationTHE NATIONAL QUALITY FORUM
National Voluntary Consensus Standards for Patient Outcomes Summary of the Diabetes/Metabolic Technical Advisory Panel Conference Call December 15, 2009: 2:00-3:30 pm Eastern Standard Time TAP Members
More informationUpdate in Cardiology Pharmacologic Management of Cardiovascular Risk. Christopher C. Roe, MSN, ACNP
Update in Cardiology Pharmacologic Management of Cardiovascular Risk Christopher C. Roe, MSN, ACNP Objectives 1. Verbalize understanding of new pharmacologic guidelines in the treatment of hypertension
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE General practice Indicators for the NICE menu
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE General practice Indicators for the NICE menu Indicator area: Pulse rhythm assessment for AF Indicator: NM146 Date: June 2017 Introduction There is evidence
More informationPatient Education. intermountainhealthcare.org/diabetes. BG Tracker. for people with diabetes MONITORING BLOOD GLUCOSE
Patient Education intermountainhealthcare.org/diabetes Tracker for people with diabetes MONITORING BLOOD GLUCOSE Title Case My name/phone: Contact numbers: Healthcare provider: Diabetes educator: Pharmacy:
More informationNew Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids.
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationRISK FACTORS FOR DIABETIC RETINOPATHY PROGRESSION
2015 ILEX PUBLISHING HOUSE, Bucharest, Roumania http://www.jrdiabet.ro Rom J Diabetes Nutr Metab Dis. 22(2):159-165 doi: 10.1515/rjdnmd-2015-0020 RISK FACTORS FOR DIABETIC RETINOPATHY PROGRESSION Mónika
More informationMedi-Cal Managed Care Plans: Diabetes Care HEDIS Measures. July 2016 California Health Policy Strategies
Medi-Cal Managed Care Plans: Diabetes Care HEDIS Measures July 2016 California Health Policy Strategies Introduction to HEDIS Measures Both Medi-Cal Managed Care plans and commercial plans are required
More informationLIPITOR AND YOU HELPFUL INFORMATION FOR UNDERSTANDING CHOLESTEROL AND RISKS
LIPITOR AND YOU HELPFUL INFORMATION FOR UNDERSTANDING CHOLESTEROL AND RISKS Learn what your cholesterol levels actually mean, and how you may save money on your prescription each month with the LIPITOR
More informationQualification Form Instructions
Qualification Form Instructions Congratulations on taking steps toward maintaining or improving your health! The Blue Cross Blue Shield of Michigan Qualification Form is enclosed for you and your physician
More informationVariation in Care Improvement Opportunities Suggests Need for Tailored Clinician-Specific Improvement Interventions
Variation in Care Improvement Opportunities Suggests Need for Tailored Clinician-Specific Improvement Interventions Jeffrey P. Anderson, ScD, MPH 1 ; JoAnn M. Sperl-Hillen, MD 1,2 ; A. Lauren Crain, PhD
More informationSupplementary Online Content
Supplementary Online Content Leibowitz M, Karpati T, Cohen-Stavi CJ, et al. Association between achieved low-density lipoprotein levels and major adverse cardiac events in patients with stable ischemic
More informationLab Values Explained. working at full strength. Other possible causes of an elevated BUN include dehydration and heart failure.
Patient Education Lab Values Explained Common Tests to Help Diagnose Kidney Disease Lab work, urine samples and other tests may be given as you undergo diagnosis and treatment for renal failure. The test
More informationMercy Diabetes Prevention Program
Mercy Diabetes Prevention Program Know the risk. Make the change. Live your life. Ashton Caton, Community Wellness Program Manager May 11, 2018 The Statistics DIABETES 30.3 million Americans People who
More informationEconomics of Reducing Out-of-Pocket Costs for Cardiovascular Preventive Services for Patients with High Blood Pressure and High Cholesterol
s of Reducing Out-of-Pocket Costs for Cardiovascular Preventive Services for Patients with High Blood Pressure and High Cholesterol Summary Evidence Tables Study Author (Year) Bunting (2008) Prepost Incomplete
More informationSect S io ecn ti 1 o : n Trend 1: Tres nds
Section 1: 1: Trends 1 Patients in the Diabetes Register 2 Gender of Patients with Diabetes 2 Age of Patients with Diabetes 3 Diabetes Type 3 Duration of Diabetes 4 Weight Control 5 Hemoglobin A1c 6 Blood
More informationPresenter. Rebecca Susic Director Account Management MEDai
Presenter Rebecca Susic Director Account Management MEDai Agenda The Chronic Care Problem Market Needs Risk Navigator Guidelines ROI Company Overview Summary and Discussion The Chronic Care Dilemma Seventy-five
More informationManagement of Lipid Disorders and Hypertension: Implications of the New Guidelines
Management of Lipid Disorders and Hypertension Management of Lipid Disorders and Hypertension: Implications of the New Guidelines Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine
More informationEvaluation of Chronic Kidney Disease KDIGO. Paul E de Jong University Medical Center Groningen The Netherlands
Evaluation of Chronic Kidney Disease Paul E de Jong University Medical Center Groningen The Netherlands Evaluation and Management of CKD 1. Definition and classification of CKD 2. Definition and impact
More informationNational Chronic Kidney Disease Audit
National Chronic Kidney Disease Audit // National Report: Part 2 December 2017 Commissioned by: Delivered by: // Foreword by Fiona Loud And if, as part of good, patient-centred care, a record of your condition(s),
More informationDyslipidemia in the light of Current Guidelines - Do we change our Practice?
Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease
More informationOutline. Outline. Introduction CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 8/11/2011
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationQUALITY IMPROVEMENT TOOLS
QUALITY IMPROVEMENT TOOLS QUALITY IMPROVEMENT TOOLS The goal of this section is to build the capacity of quality improvement staff to implement proven strategies and techniques within their health care
More information4/7/ The stats on heart disease. + Deaths & Age-Adjusted Death Rates for
+ Update on Lipid Management Stacey Gardiner, MD Assistant Professor Division of Cardiovascular Medicine Medical College of Wisconsin + The stats on heart disease Over the past 10 years for which statistics
More information2017 Diabetes. Program Evaluation. Our mission is to improve the health and quality of life of our members
2017 Diabetes Program Evaluation Our mission is to improve the health and quality of life of our members Diabetes Program Evaluation Program Title: Diabetes Program Evaluation Period: January 1, 2017 December
More informationStatus of the CKD and ESRD treatment: Growth, Care, Disparities
Status of the CKD and ESRD treatment: Growth, Care, Disparities United States Renal Data System Coordinating Center An J. Collins, MD FACP Director USRDS Coordinating Center Robert Foley, MB Co-investigator
More information2016 EUROPEAN GUIDELINES ON CVD PREVENTION IN CLINICAL PRACTICE
2016 EUROPEAN GUIDELINES ON CVD PREVENTION IN CLINICAL PRACTICE Massimo F Piepoli, MD, PhD, FESC, Piacenza, Italy on behalf of the 6 th Joint Task Force 2 3 Guidelines still based upon the principles of
More informationOutline. Introduction. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 6/26/2012
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationCHRONIC RENAL FAILURE: WHAT THE PRIMARY CARE CAN OFFER. The annual conference of the Lebanese Society of Family Medicine October 2017 Dr Hiba AZAR
CHRONIC RENAL FAILURE: WHAT THE PRIMARY CARE CAN OFFER The annual conference of the Lebanese Society of Family Medicine October 2017 Dr Hiba AZAR OUTLINE: A journey through CKD Screening for CKD: The why,
More informationImplementing Performance Measurement Programs: The Blue Cross Blue Shield of Massachusetts Perspective
Implementing Performance Measurement Programs: The Blue Cross Blue Shield of Massachusetts Perspective Dana Gelb Safran, Sc.D. Senior Vice President Performance Measurement and Improvement Massachusetts
More informationWomen and Vascular Disease
Women and Vascular Disease KEVIN F. REBECK PA-C VASCULAR TRANSPLANT SURGERY 1 The Scope of the Problem One woman dies every minute from cardiovascular disease in the U.S.! The Scope of the Problem CVD
More informationClinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial
Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial RP Giugliano, TR Pedersen, AC Keech, PS Sever, JG Park, and MS Sabatine,
More informationReport Operation Heart to Heart
Report Operation Heart to Heart Elkhorn Logan Valley Public Health Department (Burt, Cuming, Madison, and Stanton Counties) Gina Uhing, Health Director Ionia Research Newcastle, Nebraska Joseph Nitzke
More informationSpotty Calcification as a Marker of Accelerated Progression of Coronary Atherosclerosis : Insights from Serial Intravascular Ultrasound
Spotty Calcification as a Marker of Accelerated Progression of Coronary Atherosclerosis : Insights from Serial Intravascular Ultrasound Department of Cardiovascular Medicine Heart and Vascular Institute
More informationDyslipidemia and Combination Therapy: A Framework for Clinical Decision Making
Dyslipidemia and Combination Therapy: A Framework for Clinical Decision Making Shashank Sinha, MD Pamela B. Morris, MD, FACC 8 October 2016 Mexico City Introduction: Pamela B. Morris, MD, FACC COMING TO
More informationABCD and Renal Association Clinical Guidelines for Diabetic Nephropathy-CKD. Management of Dyslipidaemia and Hypertension in Adults Dr Peter Winocour
ABCD and Renal Association Clinical Guidelines for Diabetic Nephropathy-CKD. Management of Dyslipidaemia and Hypertension in Adults Dr Peter Winocour Dr Indranil Dasgupta Rationale No national practical
More informationElevation of Serum Creatinine: When to Screen, When to Refer. Bruce F. Culleton, MD, FRCPC; and Jolanta Karpinski, MD, FRCPC
Elevation of Serum Creatinine: When to Screen, When to Refer Bruce F. Culleton, MD, FRCPC; and Jolanta Karpinski, MD, FRCPC Presented at the University of Calgary s CME and Professional Development 2006-2007
More informationLifetime clinical and economic benefits of statin-based LDL lowering in the 20-year Followup of the West of Scotland Coronary Prevention Study
Lifetime clinical and economic benefits of statin-based LDL lowering in the 20-year Followup of the West of Scotland Coronary Prevention Study Harvey White Green Lane Cardiovascular Service and Cardiovascular
More informationClient Report Screening Program Results For: Missouri Western State University October 28, 2013
Client Report For: Missouri Western State University October 28, 2013 Executive Summary PROGRAM OVERVIEW From 1/1/2013-9/30/2013, Missouri Western State University participants participated in a screening
More information